© 2022 MJH Life Sciences and NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Recommendations to neurologists on appropriately prescribing and managing patients with relapsing-remitting multiple sclerosis using novel, oral therapies.
November 23rd 2021
The patient symptoms that help neurologists distinguish relapsing and remitting multiple sclerosis from other forms of the disease, and recommendations regarding the best timing to initiate therapy.
The rationale for early treatment initiation for patients with relapsing-remitting multiple sclerosis.
December 1st 2021
Best practices for talking about treatment goals and options with patients who have relapsing-remitting multiple sclerosis.
Considerations that affect recommendations for novel oral treatment for relapsing-remitting multiple sclerosis vs a more conventional option.
December 6th 2021
Experts discuss types of oral fumarates that are available to treat relapsing-remitting multiple sclerosis, and best practices for selecting an option based on trial data and clinical experience.
What to know about using S1P receptor modulators as oral therapy for relapsing-remitting multiple sclerosis.
December 15th 2021
Considerations that affect which S1P receptor modulator may be used to treat relapsing-remitting multiple sclerosis, and how to best utilize them during COVID-19.
The advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.
December 22nd 2021
Characteristics that make the purine antimetabolite, cladribine, a unique treatment option for relapsing-remitting multiple sclerosis.
Following previous discussions about novel oral therapies available as treatment for relapsing-remitting multiple sclerosis, a small panel of neurologists comment on factors that affect which agent they select.
Migraine Frequency and Aura Impacts Sensory Organization
AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant
NeurologyLive® Friday 5 — May 27, 2022
Neurology on the Hill 2022: Takeaways and Progress